Flow cytometric analysis of Human CD19 expression on Human PBMC. Human PBMC (peripheral blood mononuclear cells) were stained with either FITC Mouse IgG1 Isotype Control (Left panel) or FITC Mouse Anti-Human CD19 Antibody (Right panel) at 1.25 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
FITC Mouse Anti-Human CD19 Antibody (S-R503-2)
FITC Mouse Anti-Human CD19 Antibody (S-R503-2)
Price:
Regular price
$92.00 SGD
Regular price
Sale price
$92.00 SGD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD19 |
| Synonyms | B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12 |
| Location | Cell membrane |
| Accession | P15391 |
| Clone Number | S-R503-2 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1 |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD19, also known as B-lymphocyte antigen CD19 or B-Lymphocyte Surface Antigen B4, is a 95 kDa type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily and is encoded by the CD19 gene. It is primarily expressed on all B lineage cells, from early pro-B cells to plasma cells, and plays a crucial role in B cell development, activation, and signaling. As a co-receptor, CD19 enhances signaling through the B cell receptor (BCR) complex, lowering the threshold for B cell activation and promoting B cell proliferation and differentiation. It forms a complex with CD21, CD81, and other proteins, which helps in the recognition of antigens tagged with complement and amplifies BCR signaling. CD19 is also a biomarker for B cell-related diseases and a target for immunotherapies, including monoclonal antibodies and CAR-T cell therapies, due to its consistent expression on B cells and B cell malignancies.
Picture
Picture
FC
